169251 ⎘
Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing; Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses; Viruses HIV or HTLV
ANTIBODY AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 P24 AND TYPE 2 P26 AND USES THEREOF
#2Sexually Transmitted Infection Testing from Human Dried Blood Spots Collected Remotely
#3SIV ENVELOPE TRIMER
#4Sequential sample adding device and automatic sequential sample adding system
#5HIV GP41 VARIANTS FOR IMMUNODIAGNOSTIC ASSAYS
#6DNA DISPLAY OF FOLDED RNA LIBRARIES ENABLING RNA-SELEX WITHOUT REVERSE TRANSCRIPTION
#7ANTIBODY SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#8NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#9IMMUNOGENS AND VACCINE COMPOSITIONS AGAINST HIV
#10NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE
#11BISPECIFIC ANTIBODIES TO HIV-1 ENV AND THEIR USE
#12NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#13BROADLY NEUTRALIZING ANTI-HIV ANTIBODIES AND EPITOPE THEREFOR
#14RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION
#15ASSAY METHODS
#16Methods and compositions for assessing antibody specificities
#17LUMINESCENT BASED ANTIGEN ASSAY
#18METHOD AND COMPOSITIONS FOR THE TREATMENT AND DETECTION OF ENDOTHELIN-1 RELATED KIDNEY DISEASES
#19Anti-HVEM Antibodies
#20Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells
#21ANTI-HUMAN IMMUNODEFICIENCY VIRUS-1 ANTIBODIES AND METHODS FOR USES THEREOF
#22Conformationally Specific Viral Immunogens
#23HUMAN IMMUNODEFICIENCY VIRUS (HIV) ANTIGENS AND EPITOPES AND PROTEINS THAT BIND THERETO
#24TEST KITS, DEVICES AND METHODS FOR DETECTING HIV INFECTION
#25HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST THE MEMBRANE-PROXIMAL EXTERNAL REGION OF HIV ENV FOR VACCINE DESIGN AND INTERVENTION
#26TRANSGLUTAMINASE SUBSTRATES FOR LABELING
#27Methods and compositions for assessing antibody specificities
#28CLICK CHEMISTRY AMPLIFIED NANOPORE ASSAY FOR ULTRASENSITIVE QUANTIFICATION OF PROTEINS
#29METHODS AND COMPOSITIONS USING NON-INVASIVE PLASMA GLYCOMIC AND METABOLIC BIOMARKERS OF POST-TREATMENT CONTROL OF HIV
#30RAPID QUANTITATIVE ASSAY TO ASSESS DURATION OF INFECTION
#31ANTIBODY-LINKED IMMUNO-SEDIMENTATION AGENT AND METHOD OF ISOLATING A TARGET FROM A SAMPLE USING SAME
#32METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES
#33Recombinant HIV-1 envelope proteins and their use
#34Neutralizing antibodies to GP120 and their use
#35METHOD FOR DIAGNOSING HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 (HTLV-1)-RELATED DISEASE
#36COMPOSITIONS AND METHODS BASED ON HIV GP120 MUTANTS
#37ANTIBODY SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#38METHODS AND SYSTEMS FOR RAPID DETECTION OF SARS-COV-2 USING A RADIOLABELED ANTIBODY
#39ANTIBODIES AND THE USES THEREOF
#40EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES
#41HIV BINDING AGENTS
#42METHOD AND COMPOSITIONS FOR THE TREATMENT AND DETECTION OF ENDOTHELIN-1 RELATED KIDNEY DISEASES
#43EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES
#44SYSTEM AND METHOD FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO A TREATMENT REGIMEN
#45ANTIVIRAL IMMUNOTHERAPY BY MEMBRANE RECEPTOR LIGATION
#46METHOD FOR DIAGNOSING HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 (HTLV-1) ASSOCIATED DISEASES
#47METHODS AND COMPOSITIONS FOR REDUCING NUMBERS OR ELIMINATING HIV-INFECTED CELLS
#48HIV SEROSIGNATURES FOR CROSS-SECTIONAL INCIDENCE ESTIMATION
#49Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
#50ANTI-HIV ANTIBODIES
#51Recombinant gp120 protein with V1-loop deletion
#52Method of treating autoimmune inflammatory crohn's disease
#53Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
#54NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#55SIV ENVELOPE TRIMER
#56Conformationally-specific viral immunogens
#57IMMUNOASSAY UTILIZING TRAPPING CONJUGATE
#58Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
#59HIV antibody derivatives with dual antiviral and immunomodulatory activities from CD4 and GP41
#60Assay methods
#61NOVEL MAMMALIAN EXPRESSED HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE PROTEIN ANTIGENS
#62Synthetic peptide for detecting HIV-1
#63METHODS AND APPARATUS FOR CONDUCTING MULTIPLE MEASUREMENTS ON A SAMPLE
#64Methods and compositions for assessing antibody specificities
#65Immunoassay Methods Utilizing Trapping Conjugate
#66Neutralizing antibodies to HIV-1 Env and their use
#67Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
#68MULTIVALENT MONO- OR BISPECIFIC RECOMBINANT ANTIBODIES FOR ANALYTIC PURPOSE
#69METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES
#70Methods of making anti-GP41 antibody-specific capture agents
#71ASSAY METHODS FOR IMPROVED ANALYTE DETECTION
#72RAPID QUANTITATIVE ASSAY TO ASSESS DURATION OF INFECTION
#73IMPROVED METHODS FOR MONITORING IMMUNE STATUS OF A SUBJECT
#74Treatment and diagnosis of inflammatory disorders and HIV
#75SYSTEMS and METHODS for DETECTING INFECTIOUS DISEASES
#76Polypeptides which bind C-X-C chemokine receptor type 4 (CXCR4) and methods of treating or reducing the risk of fibrosis and cancer
#77NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#78Substituted heterocycles for targeting Hsp90
#79Labeled complex, preparation method thereof, kit containing the same, application of kit and detection system comprising kit
#80Nucleic acids encoding broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 ENV subunits
#81Accurate, rapid and convenient single-step disease diagnostic method using self-amplification principle of detection signal
#82Polyclonal antibodies produced using HIV-1 trimeric envelope glycoprotein subunits
#83Compounds that bind to human immunodeficiency virus rev response element
#84Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
#85Exosome-mediated diagnosis of human immunodeficiency virus infection
#86Soluble and immunoreactive variants of HTLV capsid antigen P24
#87Method for isolating HIV reservoir cells expressing CD32a cell marker
#88SYSTEMS and METHODS for DETECTING INFECTIOUS DISEASES
#89Recombinant HIV-1 envelope proteins and their use
#90Methods and compositions for assessing antibody specificities
#91Exosome-mediated diagnosis of hepatitis virus infections and diseases
#92Method for detecting HIV-1 co-receptor tropism
#93METHODS AND APPARATUS FOR CONDUCTING MULTIPLE MEASUREMENTS ON A SAMPLE
#94Method for the detection of cells associated with the latent HIV viral reservoir using membrane biomarkers
#95Method for detecting HIV-1-specific antibodies using clade C env polypeptides
#96Antibody-linked immuno-sedimentation agent and method of isolating a target form a sample using same
#97HIV CLINICAL PLAN
#98Treatment and diagnosis of inflammatory disorders and HIV
#99HIV DIAGNOSTIC METHOD USING CD4 AND CD8 CELL INFORMATION
#100Conformationally Specific Viral Immunogens
#101Sample mixing control
#102SCREENING METHODS FOR IDENTIFYING AND TREATING HIV-1 INFECTED PATIENT SUB-POPULATIONS SUITABLE FOR LONG TERM ANTI-CCR5 AGENT THERAPY
#103Antiviral immunotherapy by membrane receptor ligation
#104ASSAY DEVICE AND METHOD
#105Substituted heterocycles for targeting HSP90
#106Compositions and Methods for Evaluating Viral Receptor/Co-Receptor Usage and Inhibitors of Virus Entry Using Recombinant Virus Assays
#107Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein
#108Methods for determining the risk of cardiovascular disease in a subject having a chronic viral infection through the measurement of lysophosphatidic acid
#109Neutralizing antibodies to gp120 and their use
#110Immunoassay utilizing trapping conjugate
#111Immunoassay utilizing trapping conjugate
#112Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
#113Immunoassay utilizing trapping conjugate
#114HIV VPR-specific T-cell receptors
#115Conformationally specific viral immunogens
#116Treatment and diagnosis of inflammatory disorders and HIV
#117Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
#118HIGH SENSITIVITY MEDICAL DEVICE AND MANUFACTURING THEREOF
#119CXCR4 binding molecules and methods of use thereof
#120Compositions for preventing and/or treating an infection by an HIV-1 virus
#121Immunoassay methods utilizing trapping conjugate
#122Multi-color reporter cells for detecting HIV-1
#123Human factor XIII as a normalization control for immunoassays
#124Neutralizing GP41 antibodies and their use
#125Substituted 6-aminopurines for targeting HSP90
#126Methods for modular synthesis of N-glycans and arrays thereof
#127Cell identification method
#128Measuring HIV reservoirs with optical scanning
#129PREVENTION AND TREATMENT OF INFECTIONS
#130Methods for simultaneous determination of serological profile and estimation of duration post HIV infection
#131EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES
#132Levels of CXCL10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS
#133Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
#134HIGH SENSITIVTY MEDICAL DEVICE AND MANUFACTURING THEREOF
#135Human factor XIII as a normalization control for immunoassays
#136Recombinant HIV-1 envelope proteins and their use
#137Diagnostic devices, systems, and methods
#138Soluble and immunoreactive variants of HTLV capsid antigen p24
#139Exosome-mediated diagnosis of hepatitis virus infections and diseases
#140Systems and methods for detecting infectious diseases
#141Assay methods
#142Biomarkers for assessing HIV
#143Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
#144MICROFLUIDIC CAPTURE AND DETECTION OF BIOLOGICAL ANALYTES
#145WAVEGUIDE-BASED DETECTION SYSTEM WITH SCANNING LIGHT SOURCE
#146TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS
#147DEVICES, SYSTEMS AND METHODS FOR DIAGNOSTIC TESTING
#148Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent
#149Exosome-mediated diagnosis of hepatitis virus infections and diseases
#150Method for the vaccination against HIV
#151Use of protein nanoparticle based hydrogel
#152Treatment and diagnosis of inflammatory disorders and HIV
#153Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies
#154Use of antagonists of the interaction between HIV GP120 and α4β7 integrin
#155Neutralizing GP41 antibodies and their use
#156Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
#157Methods for inhibiting HIV or HCV infection by administering TIM-3 binding inhibitors
#158HIV-1 broadly neutralizing antibodies
#159METHODS AND APPARATUS FOR CONDUCTING MULTIPLE MEASUREMENTS ON A SAMPLE
#160Compounds that bind to human immunodeficiency virus rev response element
#161NOVEL NON-INVASIVE METHODS OF MONITORING HIV VIRAL LOADS
#162Methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays
#163Cyclic HIV-1 Env V3 glycopeptide immunogens
#164Use of antagonists of the interaction between HIV GP120 and α4β7 integrin
#165Systems and methods for detecting infectious diseases
#166Compositions for preventing and/or treating an infection by an HIV-1 virus
#167HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders
#168Molecules inhibiting the human immunodeficiency virus type 1 (HIV-1), method for the production thereof and applications of same
#169Solid support comprising HIV-1 clade C envelope peptides for the detection of HIV-1-specific antibodies
#170RAPID TESTS FOR INSURANCE UNDERWRITING
#171Treating human immunodeficiency virus infections
#172METHOD OF THERAPY
#173SYSTEM AND METHOD FOR IMPROVING BIOMARKER ASSAY
#174Plasma cytochrome C as a biomarker for mitochondrial toxicity during antiretroviral therapy
#175Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles
#176System and method for detecting pathogens
#177Systems and methods for detecting infectious diseases
#178Immunoassay methods utilizing trapping conjugate
#179Immunoassay utilizing trapping conjugate
#180Piperidine derivatives and methods of treating hepatitis B infections
#181Density Amplification in Magnetic Levitation to Detect Binding Events of Large Molecules
#182Levels of CXCL 10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS
#183Compositions and methods for measles virus inhibition
#184Methods for identifying HIV neutralizing antibodies
#185Treatment and diagnosis of inflammatory disorders and HIV
#186Substituted indazoles for targeting Hsp90
#187Peptide inhibitors as novel anti-HIV therapeutics
#188Method for diagnosing and differentiating HIV-2 infections
#189FRET-based reagents and methods for identifying anti-HIV compounds
#190Detection, capture and quantification of biological moieties from unprocessed bodily fluids using nanoplasmonic platform
#191HIV antigens and antibodies and compositions, uses and methods thereof
#192Compositions and Methods for Reactivating Latent Immunodeficiency Virus
#193METHODS OF DETECTING CELLS LATENTLY INFECTED WITH HIV
#194TESTING DEVICE
#195Portable rapid diagnostic test reader and methods of using the same
#196Apparatus and method for virus detection
#197Anti-GP41 antibody-specific capture agents, compositions, and methods of using and making
#198Immunogenic compositions comprising FIV and HIV gag antigens
#199HIV vpr-specific T-cell receptors
#200Systems and methods for detecting infectious diseases
#201Systems and methods for detecting infectious diseases
#202METHODS OF IDENTIFYING NOVEL HIV-1 IMMUNOGENS
#203METHOD OF INTRACELLULAR INFECTIOUS AGENT DETECTION IN SPERM CELLS
#204Method for monitoring HIV specific T cell responses
#205Dual path immunoassay device
#206Method for quantitating total HMGB1 protein in biological samples
#207COMPOSITIONS, METHODS, AND KITS FOR ENHANCING THE IMMUNOGENICITY OF PATHOGENIC ANTIGENS
#208Detecting and quantifying cryptic HIV replication
#209Alpha1 proteinase inhibitor peptides methods and use
#210Semi-quantitative lateral flow assays
#211Method for blocking HIV entry into dendritic cells by inhibiting sialoadhesin-sialyllactose binding interactions with gangliosides
#212Biomarkers for Tuberculosis and HIV/AIDS
#213METHODS FOR DETERMINING THE SUSCEPTIBILITY OF A VIRUS TO AN ATTACHMENT INHIBITOR
#214Neutralizing GP41 antibodies and their use
#215Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
#216HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders
#217HIV-1 gp120 mini V3 loop and uses thereof
#218Assay methods
#219DETECTION OF HUMAN ENDOGENOUS RETROVIRUS EXPRESSION IN CANCER AND NORMAL CELLS
#220Method for detecting HIV-1 co-receptor tropism
#221Monoclonal antibodies directed against a novel pathogenic west African human immunodeficiency virus type 2 (HIV-2) group F isolate
#222Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing
#223Low-cost point-of-care assay device
#224Exosome-mediated diagnosis of hepatitis virus infections and diseases
#225Assay device and method
#226USE OF PROTEIN NANOPARTICLE BASED HYDROGEL
#227High sensitivity medical device and manufacturing thereof
#228Methods, compositions, and kits for determining human immunodeficiency virus (HIV)
#229Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
#230Antigenic polypeptides comprising pre-hairpin intermediate conformations of HIV-1 GP41
#231Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
#232Assay method for peptide specific T-cells
#233Virus traps
#234Compositions and methods for coronavirus inhibition
#235Dual path immunoassay device
#236GLYCAN IMMOBILIZED METAL NANOPARTICLES AND USE THEREOF FOR EARLY HIV-1 DETECTION
#237Rapid selection method for HIV gp-120 variants
#238Compositions for detecting an infection by an HIV-1 virus
#239Human factor XIII as a normalization control for immunoassays
#240ANIMAL MODEL FOR THE EVALUATION OF THE EFFICACY OF AN HIV VACCINE
#241Conformationally Specific Viral Immunogens
#242DEVICES AND METHODS FOR DETECTING ANALYTE IN BODILY FLUID
#243Active cores of peptide triazole HIV-1 entry inhibitors
#244Compounds and therapeutic applications related to inhibition of dendritic cell immunoreceptor (DCIR) activity and signaling events
#245Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
#246Portable rapid diagnostic test reader
#247Stabilized leukocytes and their use
#248Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope
#249Detection of feline immunodeficiency virus
#250Peptides mimicking HIV-1 viral epitopes in the V2 loop for the GP120 surface envelope glycoprotein
#251HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders
#252DEVICES AND METHODS FOR DETECTING AND MONITORING HIV AND OTHER INFECTIONS AND DISEASES
#253CELL FREE CD4 QUANTITATION AND METHODS OF USE
#254RAPID TEST FOR DETECTING INFECTION
#255Biomarkers to identify HIV-specific T-cell subsets
#256MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION
#257Treatment of influenza virus infection
#258TRIM5alpha mutants and uses thereof
#259LYMPHOCYTE ANALYSIS FOR MONITORING THE PROGRESSION OF IMMUNODEFICIENCY VIRUS
#260Treatment and diagnosis of inflammatory disorders and HIV
#261Mutational profile in HIV-1 GAG cleavage site correlated with phenotypic drug resistance
#262Detection of HIV-related proteins in urine
#263Detection of HIV-related proteins in urine
#264Method for the detection of HIV-1-specific antibodies utilizing a Vpu polypeptide
#265ALPHABODIES FOR HIV ENTRY INHIBITION
#266Active cores of peptide triazole HIV-1 entry inhibitors
#267Method of therapy
#268Pathogenic west african human immunodeficiency virus type 2 (HIV-2) group F isolate
#269Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
#270Method for inhibiting dendritic cell immunoreceptor (DCIR)-mediated human immunodeficiency virus infection comprising administering anti-DCIR antibodies
#271Antiviral agent
#272Immunoassay Device for Detecting Antibodies and Antigens
#273Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
#274Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
#275OVERLAPPING PEPTIDES FROM VARIABLE ANTIGENS, T CELL POPULATIONS AND USES THEREOF
#276Method of detecting antibodies and antibody-hiv virion complexes
#277BIOSENSOR FOR DETECTING ANTI-HIV ANTIBODIES
#278DIAGNOSTIC AND THERAPEUTIC PROTOCOLS
#279Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
#280Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
#281Rapid expression cloning of human monoclonal antibodies from memory B cells
#282HIV-1 Envelope Based Fragments
#283METHODS FOR MAKING HIV VACCINES AND RELATED COMPOSITIONS
#284Viral Therapeutic
#285Nucleic acid ligand complexes
#286Methods for the detection of HIV-1-specific antibodies employing GP41 polypeptides
#287COMPOSITIONS, METHODS, AND KITS FOR ENHANCING THE IMMUNOGENICITY OF PATHOGENIC ANTIGENS
#288TAT-BASED IMMUNOMODULATORY COMPOSITIONS AND METHODS FOR THEIR DISCOVERY AND USE
#289Method and Device for Detecting Feline Immunodeficiency Virus
#290Glycan markers and autoantibody signatures in HIV-1 and HIV-1-associated malignancies
#291Methods, agents and peptides for inducing an innate immune response in HIV vaccination
#292Compounds that Inhibit HIV Particle Formation
#293COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION
#294Methods and apparatus for conducting multiple measurements on a sample
#295Methods of Detecting Inhibitors of VIF-Mediated APOBEC3G Degradation and HIV
#296Peptides and methods of use as therapeutics and screening agents
#297NANO AND MICRO-TECHNOLOGY VIRUS DETECTION METHOD AND DEVICE
#298Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
#299IMMORTALIZED HUMAN CD4-POSITIVE CELL AND ITS USE FOR DETERMINING THE PHENOTYPE OF A HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
#300Methods for determining the presence of antibodies blocking viral infection